Which diabetes pill is better for Early-Stage patients? major trial compares dapagliflozin and metformin
NCT ID NCT03982381
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared two common diabetes drugs—dapagliflozin and metformin—in over 2,000 people with early type 2 diabetes (diagnosed less than 4 years). The goal was to see which drug better prevents serious complications like death, heart attack, stroke, heart failure, kidney disease, eye problems, and foot ulcers. Participants took either dapagliflozin or metformin, and researchers tracked their health using national registries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a drug that lowers blood sugar by helping the kidneys remove sugar through urine)
What this could lead to
If dapagliflozin works better than metformin, it could become a preferred first treatment for early type 2 diabetes to reduce the risk of serious complications like heart attack, stroke, and kidney disease.
What could go wrong
This is a completed Phase 4 trial, but it is open-label (patients and doctors know the treatment), which can bias results. Also, the benefit may be small or not apply to all patients with early diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uppsala University Hospital
Uppsala, 75185, Sweden